Search Result
Results for "
dopaminergic system
" in MedChemExpress (MCE) Product Catalog:
5
Isotope-Labeled Compounds
| Cat. No. |
상품명 |
Target |
연구분야 |
Chemical Structure |
-
- HY-105174
-
|
|
JAK
FAK
|
Inflammation/Immunology
|
|
BPC 157 is the 15-amino acide fragment of gastric peptide BPC. BPC 157 exhibits wound healing promoting and neuroprotective activity. BPC 157 maintains the integrity of the gastrointestinal mucosa without significant toxicity. BPC 157 acetate counteracts NSAIDs/insulin overdose/copper-induced toxicity. BPC 157 ameliorates specific (over)stimulated/damaged neurotransmitter systems-induced behavioral disorders through serotonergic and dopaminergic systems .
|
-
-
- HY-B1065
-
|
α-N-Acetyl-L-glutamine; N2-Acetylglutamine
|
Keap1-Nrf2
Akt
ASK1
Apoptosis
|
Neurological Disease
|
|
Aceglutamide (α-N-Acetyl-L-glutamine; N2-Acetylglutamine) is a neuroprotectant that can penetrate the blood-brain barrier. Aceglutamide can enhance the antioxidant systems of glutathione (GSH), thioredoxin (Trx) and Nrf2. Aceglutamide also inhibits ASK1 and TRAF1, activates the Akt/Bcl-2 anti-apoptotic pathway, enhances the activity of antioxidant enzymes and reduces oxidative damage. Aceglutamide can improve neurological deficits after cerebral ischemia, reduce infarct volume, and inhibit neuronal apoptosis, especially substantia nigra dopaminergic neurons. Aceglutamide can reduce cerebral ischemia/reperfusion injury, improve motor dysfunction, and is used in ischemic stroke-related research .
|
-
-
- HY-113468A
-
|
3-Methoxy-L-tyrosine; 3-O-Methyl-L-DOPA
|
Drug Derivative
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
|
3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa has certain antidepressant and neuroprotective activities. 3-O-Methyldopa can be used in the research of nervous system diseases such as depression and Parkinson's disease .
|
-
-
- HY-100705
-
|
6-Nitroveratraldehyde
|
Drug Intermediate
|
Neurological Disease
|
|
DMNB (6-Nitroveratraldehyde) is a photolabile proton donor that releases acidic substances when excited at a wavelength of 405 nM. DMNB can be used for the synthesis of no-carrier-added 6-[18F]fluoro-L-DOPA (6-FDOPA). DMNB is also applicable to the preparation of o-nitroaryl-bis (5-methylfur-2-yl) methanes and the synthesis of alpha-asarone (HY-N0700). DMNB is an enzyme involved in the non-homologous end joining (NHEJ) pathway responsible for DNA double-strand break (DSB) repair. DMNB can be used in PET studies of the dopaminergic system .
|
-
-
- HY-159829
-
|
NBI-1117568; HTL-0016878
|
mAChR
|
Neurological Disease
|
|
Direclidine (NBI-1117568, HTL-0016878) is a selective orthosteric agonist targeting the muscarinic acetylcholine M4 receptor, exhibiting very low affinity for M1, M2, M3, and M5 receptors. It binds to the orthosteric site of the M4 receptor in a non-covalent, competitive manner. Direclidine specifically activates the M4 receptor, inhibiting the release of acetylcholine from striatal cholinergic interneurons, thereby regulating the balance of the dopaminergic system and reducing psychiatric symptoms associated with excessive dopamine release. Direclidine can improve symptoms associated with neuropsychiatric disorders and is used in research on schizophrenia and other neuropsychiatric disorders .
|
-
-
- HY-113468AS
-
|
3-Methoxy-L-tyrosine-d3; 3-O-Methyl-L-DOPA-d3
|
Isotope-Labeled Compounds
Drug Metabolite
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
|
3-O-Methyldopa-d3 (3-Methoxy-L-tyrosine-d3) is deuterium labeled 3-O-Methyldopa (HY-113468A). 3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa has certain antidepressant and neuroprotective activities. 3-O-Methyldopa can be used in the research of nervous system diseases such as depression and Parkinson's disease .
|
-
-
- HY-U00051
-
|
|
Histamine Receptor
Dopamine Receptor
|
Neurological Disease
|
|
Propiomazine is an orally active antihistamine agent. Propiomazine is a potent prolactin (PRL) release stimulant, whose effect depends on the antagonism of the dopaminergic system and can inhibit the secretion of luteinizing hormone (LH). Propiomazine is mainly used for anesthesia assistance, mental disorders and anxiety-induced sedation, and can also be used in research related to insomnia .
|
-
-
- HY-U00280
-
|
|
Potassium Channel
|
Neurological Disease
|
|
Potassium Channel Activator 1 ((2,4-Dimethyl-6-morpholin-4-yl-pyridin-3-yl)-carbamic acid benzyl ester) is a potassium channel activator. Potassium Channel Activator 1 can be used for the study diseases or symptoms of dopaminergic system disorders .
|
-
-
- HY-103405A
-
|
|
Dopamine Receptor
|
Neurological Disease
|
|
NGD 94-1 (dimaleate) is a potent and selective dopamine D4 receptor antagonist. NGD 94-1 (dimaleate) shows high affinity for the cloned human D4.2 receptor (Ki = 3.6 nM). NGD 94-1 (dimaleate) modulates the cognitive functions of the frontostriatal system and regulates dopaminergic transmission in Phencyclidine (PCP)-induced monkeys. NGD 94-1 (dimaleate) can be used for neurological disease research [1][2].
|
-
-
- HY-U00051A
-
|
|
Histamine Receptor
|
Neurological Disease
|
|
Propiomazine hydrochloride is an orally active antihistamine agent. Propiomazine hydrochloride is a potent prolactin (PRL) release stimulant, whose effect depends on the antagonism of the dopaminergic system and can inhibit the secretion of luteinizing hormone (LH). Propiomazine hydrochloride is mainly used for anesthesia assistance, mental disorders and anxiety-induced sedation, and can also be used in research related to insomnia .
|
-
-
- HY-U00051AS1
-
|
|
Isotope-Labeled Compounds
|
Neurological Disease
|
|
(R)-Propiomazine-d6 hydrochloride is deuterium labeled Propiomazine hydrochloride. Propiomazine hydrochloride is an orally active antihistamine agent. Propiomazine hydrochloride is a potent prolactin (PRL) release stimulant, whose effect depends on the antagonism of the dopaminergic system and can inhibit the secretion of luteinizing hormone (LH). Propiomazine hydrochloride is mainly used for anesthesia assistance, mental disorders and anxiety-induced sedation, and can also be used in research related to insomnia.
|
-
-
- HY-U00051AS
-
|
|
Isotope-Labeled Compounds
Histamine Receptor
|
Neurological Disease
|
|
Propiomazine-d6 hydrochloride is deuterium labeled Propiomazine hydrochloride. Propiomazine hydrochloride is an orally active antihistamine agent. Propiomazine hydrochloride is a potent prolactin (PRL) release stimulant, whose effect depends on the antagonism of the dopaminergic system and can inhibit the secretion of luteinizing hormone (LH). Propiomazine hydrochloride is mainly used for anesthesia assistance, mental disorders and anxiety-induced sedation, and can also be used in research related to insomnia.
|
-
-
- HY-U00051AS2
-
|
|
Isotope-Labeled Compounds
|
Neurological Disease
|
|
(S)-Propiomazine-d6 hydrochloride is deuterium labeled Propiomazine hydrochloride. Propiomazine hydrochloride is an orally active antihistamine agent. Propiomazine hydrochloride is a potent prolactin (PRL) release stimulant, whose effect depends on the antagonism of the dopaminergic system and can inhibit the secretion of luteinizing hormone (LH). Propiomazine hydrochloride is mainly used for anesthesia assistance, mental disorders and anxiety-induced sedation, and can also be used in research related to insomnia.
|
-
-
- HY-19225A
-
|
KA-672; Anseculin
|
iGluR
5-HT Receptor
Adrenergic Receptor
Dopamine Receptor
|
Neurological Disease
|
|
Ensaculin free base (KA-672) is a NMDA antagonist and have high affinities to serotonergic 5-HT1A and 5-HT7 receptors, adrenergic α1, and dopaminergic D2 and D3 receptors. Ensaculin free base is a memory-enhancing agent. Ensaculin free base has the potential as an antidementia agent acting on various transmitter systems .
|
-
-
- HY-108985
-
|
EGYT-3615
|
Others
|
Neurological Disease
|
|
Trazium esilate (EGYT-3615) is an antidepressant, which influences the central dopaminergic system. Trazium esilate synergizes amphetamine, potentiates stereotypy and hypermotility. Trazium esilate blocks Apomorphine (HY-12723)-induced hypothermic and the stereotypy, and Bulbocapnine (HY-W436270)-induced cataleptic state. Trazium esilate enhances the effect of Norepinephrine (HY-13715) on isolated vas deferens of the rat .
|
-
-
- HY-103405
-
|
|
Dopamine Receptor
|
Neurological Disease
|
|
NGD94-1 is a potent and selective dopamine D4 receptor antagonist. NGD94-1 shows high affinity for the cloned human D4.2 receptor (Ki = 3.6 nM). NGD94-1 modulates the cognitive functions of the frontostriatal system and regulates dopaminergic transmission in Phencyclidine (PCP)-induced monkeys. NGD94-1 can be used for neurological disease research [1][2].
|
-
-
- HY-113468AS1
-
|
3-Methoxy-L-tyrosine-d3 hydrate; 3-O-Methyl-L-DOPA-d3 hydrate
|
Isotope-Labeled Compounds
Drug Metabolite
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
|
3-O-Methyldopa-d3 (hydrate) is the deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa (3-Methoxy-L-tyrosine) hydrate is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa hydrate inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa hydrate has certain antidepressant and neuroprotective activities. 3-O-Methyldopa hydrate can be used in the research of nervous system diseases such as depression and Parkinson's disease .
|
-
-
- HY-B1065R
-
|
α-N-Acetyl-L-glutamine (Standard); N2-Acetylglutamine (Standard)
|
Reference Standards
Keap1-Nrf2
Akt
ASK1
Apoptosis
|
Neurological Disease
|
|
Aceglutamide (α-N-Acetyl-L-glutamine; N2-Acetylglutamine) (Standard) is the analytical standard of Aceglutamide (HY-B1065). This product is intended for research and analytical applications. Aceglutamide (α-N-Acetyl-L-glutamine; N2-Acetylglutamine) is a neuroprotectant that can penetrate the blood-brain barrier. Aceglutamide can enhance the antioxidant systems of glutathione (GSH), thioredoxin (Trx) and Nrf2. Aceglutamide also inhibits ASK1 and TRAF1, activates the Akt/Bcl-2 anti-apoptotic pathway, enhances the activity of antioxidant enzymes and reduces oxidative damage. Aceglutamide can improve neurological deficits after cerebral ischemia, reduce infarct volume, and inhibit neuronal apoptosis, especially substantia nigra dopaminergic neurons. Aceglutamide can reduce cerebral ischemia/reperfusion injury, improve motor dysfunction, and is used in ischemic stroke-related research .
|
-
-
- HY-W742645
-
|
|
Endogenous Metabolite
|
Others
|
|
7α-Hydroxypregnenolone, a bioactive neurosteroid, is a key neuronal modulator of locomotion. 7α-Hydroxypregnenolone stimulates upstream migration by means of the dopaminergic system in salmon .
|
-
-
- HY-100705R
-
|
6-Nitroveratraldehyde (Standard)
|
Drug Intermediate
Reference Standards
|
Neurological Disease
|
|
DMNB (Standard) is the analytical standard of DMNB (HY-100705). This product is intended for research and analytical applications. DMNB (6-Nitroveratraldehyde), a precursor, can be used for the synthesis no-carrier-added 6-[18F]fluoro-L-DOPA (6-FDOPA). No-Carrier-Added (NCA) 6-[18F]fluoro-L-dopa (6-FDOPA) is being produced routinely for PET investigations of dopaminergic systems .
|
-
-
- HY-U00051B
-
|
|
Histamine Receptor
Dopamine Receptor
|
Neurological Disease
|
|
Propiomazine maleate is an orally active antihistamine agent. Propiomazine maleate is a potent prolactin (PRL) release stimulant, whose effect depends on the antagonism of the dopaminergic system and can inhibit the secretion of luteinizing hormone (LH). Propiomazine maleate is mainly used for anesthesia assistance, mental disorders and anxiety-induced sedation, and can also be used in research related to insomnia .
|
-
-
- HY-W415753
-
|
VUFB-15754
|
Drug Derivative
|
Neurological Disease
Inflammation/Immunology
|
|
Alaptide, a spirocyclic synthetic dipeptide and a derivative of melanocyte-stimulating hormone release-inhibiting factor (MIF), is a transdermal permeation modifier. Alaptide loaded on nanofibrous membranes accelerates the healing of skin incisions, particularly the healing of skin burns.
Alaptide is a nootropic agent, that influences the dopaminergic system and increases homovanillic acid level in the striatum of rat models. Alaptide can be used for wound healing with large damaged areas and neurological diseases research .
|
-
-
- HY-105174AR
-
|
|
Reference Standards
JAK
FAK
|
Neurological Disease
Metabolic Disease
|
|
BPC 157 acetate (Standard) is the analytical standard of BPC 157 acetate (HY-105174A). This product is intended for research and analytical applications. BPC 157 acetate is the acetate salt form of BPC 157 (HY-105174). BPC 157 acetate is the 15-amino acide fragment of gastric peptide BPC. BPC 157 acetate exhibits wound healing promoting and neuroprotective activity. BPC 157 acetate maintains the integrity of the gastrointestinal mucosa without significant toxicity. BPC 157 acetate counteracts NSAIDs/insulin overdose/copper-induced toxicity. BPC 157 acetate ameliorates specific (over)stimulated/damaged neurotransmitter systems-induced behavioral disorders through serotonergic and dopaminergic systems .
|
-
| Cat. No. |
상품명 |
Target |
Research Area |
-
- HY-105174
-
|
|
JAK
FAK
|
Inflammation/Immunology
|
|
BPC 157 is the 15-amino acide fragment of gastric peptide BPC. BPC 157 exhibits wound healing promoting and neuroprotective activity. BPC 157 maintains the integrity of the gastrointestinal mucosa without significant toxicity. BPC 157 acetate counteracts NSAIDs/insulin overdose/copper-induced toxicity. BPC 157 ameliorates specific (over)stimulated/damaged neurotransmitter systems-induced behavioral disorders through serotonergic and dopaminergic systems .
|
-
- HY-105174AR
-
|
|
Reference Standards
JAK
FAK
|
Neurological Disease
Metabolic Disease
|
|
BPC 157 acetate (Standard) is the analytical standard of BPC 157 acetate (HY-105174A). This product is intended for research and analytical applications. BPC 157 acetate is the acetate salt form of BPC 157 (HY-105174). BPC 157 acetate is the 15-amino acide fragment of gastric peptide BPC. BPC 157 acetate exhibits wound healing promoting and neuroprotective activity. BPC 157 acetate maintains the integrity of the gastrointestinal mucosa without significant toxicity. BPC 157 acetate counteracts NSAIDs/insulin overdose/copper-induced toxicity. BPC 157 acetate ameliorates specific (over)stimulated/damaged neurotransmitter systems-induced behavioral disorders through serotonergic and dopaminergic systems .
|
| Cat. No. |
상품명 |
Category |
Target |
Chemical Structure |
-
- HY-105174
-
-
-
- HY-B1065
-
|
α-N-Acetyl-L-glutamine; N2-Acetylglutamine
|
Microorganisms
Ketones, Aldehydes, Acids
Endogenous metabolite
Source Classification
|
Keap1-Nrf2
Akt
ASK1
Apoptosis
|
|
Aceglutamide (α-N-Acetyl-L-glutamine; N2-Acetylglutamine) is a neuroprotectant that can penetrate the blood-brain barrier. Aceglutamide can enhance the antioxidant systems of glutathione (GSH), thioredoxin (Trx) and Nrf2. Aceglutamide also inhibits ASK1 and TRAF1, activates the Akt/Bcl-2 anti-apoptotic pathway, enhances the activity of antioxidant enzymes and reduces oxidative damage. Aceglutamide can improve neurological deficits after cerebral ischemia, reduce infarct volume, and inhibit neuronal apoptosis, especially substantia nigra dopaminergic neurons. Aceglutamide can reduce cerebral ischemia/reperfusion injury, improve motor dysfunction, and is used in ischemic stroke-related research .
|
-
-
- HY-113468A
-
|
3-Methoxy-L-tyrosine; 3-O-Methyl-L-DOPA
|
Monophenols
Ketones, Aldehydes, Acids
Phenols
Endogenous metabolite
Source Classification
|
Drug Derivative
Interleukin Related
|
|
3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa has certain antidepressant and neuroprotective activities. 3-O-Methyldopa can be used in the research of nervous system diseases such as depression and Parkinson's disease .
|
-
-
- HY-B1065R
-
|
α-N-Acetyl-L-glutamine (Standard); N2-Acetylglutamine (Standard)
|
Structural Classification
Microorganisms
Ketones, Aldehydes, Acids
Endogenous metabolite
Source Classification
|
Reference Standards
Keap1-Nrf2
Akt
ASK1
Apoptosis
|
|
Aceglutamide (α-N-Acetyl-L-glutamine; N2-Acetylglutamine) (Standard) is the analytical standard of Aceglutamide (HY-B1065). This product is intended for research and analytical applications. Aceglutamide (α-N-Acetyl-L-glutamine; N2-Acetylglutamine) is a neuroprotectant that can penetrate the blood-brain barrier. Aceglutamide can enhance the antioxidant systems of glutathione (GSH), thioredoxin (Trx) and Nrf2. Aceglutamide also inhibits ASK1 and TRAF1, activates the Akt/Bcl-2 anti-apoptotic pathway, enhances the activity of antioxidant enzymes and reduces oxidative damage. Aceglutamide can improve neurological deficits after cerebral ischemia, reduce infarct volume, and inhibit neuronal apoptosis, especially substantia nigra dopaminergic neurons. Aceglutamide can reduce cerebral ischemia/reperfusion injury, improve motor dysfunction, and is used in ischemic stroke-related research .
|
-
| Cat. No. |
상품명 |
Chemical Structure |
-
- HY-113468AS
-
|
|
|
3-O-Methyldopa-d3 (3-Methoxy-L-tyrosine-d3) is deuterium labeled 3-O-Methyldopa (HY-113468A). 3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa has certain antidepressant and neuroprotective activities. 3-O-Methyldopa can be used in the research of nervous system diseases such as depression and Parkinson's disease .
|
-
-
- HY-U00051AS1
-
|
|
|
(R)-Propiomazine-d6 hydrochloride is deuterium labeled Propiomazine hydrochloride. Propiomazine hydrochloride is an orally active antihistamine agent. Propiomazine hydrochloride is a potent prolactin (PRL) release stimulant, whose effect depends on the antagonism of the dopaminergic system and can inhibit the secretion of luteinizing hormone (LH). Propiomazine hydrochloride is mainly used for anesthesia assistance, mental disorders and anxiety-induced sedation, and can also be used in research related to insomnia.
|
-
-
- HY-U00051AS
-
|
|
|
Propiomazine-d6 hydrochloride is deuterium labeled Propiomazine hydrochloride. Propiomazine hydrochloride is an orally active antihistamine agent. Propiomazine hydrochloride is a potent prolactin (PRL) release stimulant, whose effect depends on the antagonism of the dopaminergic system and can inhibit the secretion of luteinizing hormone (LH). Propiomazine hydrochloride is mainly used for anesthesia assistance, mental disorders and anxiety-induced sedation, and can also be used in research related to insomnia.
|
-
-
- HY-U00051AS2
-
|
|
|
(S)-Propiomazine-d6 hydrochloride is deuterium labeled Propiomazine hydrochloride. Propiomazine hydrochloride is an orally active antihistamine agent. Propiomazine hydrochloride is a potent prolactin (PRL) release stimulant, whose effect depends on the antagonism of the dopaminergic system and can inhibit the secretion of luteinizing hormone (LH). Propiomazine hydrochloride is mainly used for anesthesia assistance, mental disorders and anxiety-induced sedation, and can also be used in research related to insomnia.
|
-
-
- HY-113468AS1
-
|
|
|
3-O-Methyldopa-d3 (hydrate) is the deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa (3-Methoxy-L-tyrosine) hydrate is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa hydrate inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa hydrate has certain antidepressant and neuroprotective activities. 3-O-Methyldopa hydrate can be used in the research of nervous system diseases such as depression and Parkinson's disease .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- 상품명:
- Cat. No.:
- 수량:
- MCE Japan Authorized Agent: